Research Type: Articles

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Time to Throw in the Towel on Biosimilars

  • Mortgaging New Treatments Kicks the Can on High Drug Prices

  • Analysis of Medicare Part D Plans Shows $9B Upcharge

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • DPL Policy Tracker Collects Drug Pricing Legislation and Proposals

  • A $475,000 price tag for a new cancer drug: crazy or meh?

  • Baseball Illuminates the Problem with U.S. Drug Pricing

    Baseball Illuminates the Problem with U.S. Drug Pricing

  • DPL and Collaborators to Publish Drug Pricing Primer Series

  • Is Outcomes-Based Contracting Worth It?